Synovus Financial Corp increased Union Pac Corp (UNP) stake by 126.47% reported in 2017Q4 SEC filing. Synovus Financial Corp acquired 20,518 shares as Union Pac Corp (UNP)’s stock declined 2.36%. The Synovus Financial Corp holds 36,742 shares with $4.92M value, up from 16,224 last quarter. Union Pac Corp now has $104.63B valuation. The stock increased 1.57% or $2.08 during the last trading session, reaching $134.91. About 2.12 million shares traded. Union Pacific Corporation (NYSE:UNP) has risen 26.23% since April 25, 2017 and is uptrending. It has outperformed by 14.68% the S&P500.
The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) is a huge mover today! The stock increased 1.42% or $0.27 during the last trading session, reaching $19.62. About 259,887 shares traded. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has declined 16.25% since April 25, 2017 and is downtrending. It has underperformed by 27.80% the S&P500.The move comes after 7 months positive chart setup for the $669.00 million company. It was reported on Apr, 25 by Barchart.com. We have $20.21 PT which if reached, will make NASDAQ:AMAG worth $20.07M more.
Synovus Financial Corp decreased Csx Corp (NYSE:CSX) stake by 6,791 shares to 51,263 valued at $2.82 million in 2017Q4. It also reduced Ishares Tr (ACWX) stake by 38,873 shares and now owns 174,506 shares. General Electric Co (NYSE:GE) was reduced too.
Since March 20, 2018, it had 0 insider purchases, and 3 selling transactions for $7.37 million activity. Shares for $3.43 million were sold by KNIGHT ROBERT M JR. Whited Elizabeth F also sold $2.08 million worth of Union Pacific Corporation (NYSE:UNP) shares.
Among 29 analysts covering Union Pacific Corporation (NYSE:UNP), 14 have Buy rating, 2 Sell and 13 Hold. Therefore 48% are positive. Union Pacific Corporation had 109 analyst reports since July 24, 2015 according to SRatingsIntel. As per Tuesday, January 16, the company rating was maintained by Susquehanna. Deutsche Bank maintained it with “Buy” rating and $103 target in Friday, October 23 report. The rating was maintained by Loop Capital on Monday, October 30 with “Hold”. The firm has “Hold” rating given on Thursday, July 20 by Oppenheimer. The stock of Union Pacific Corporation (NYSE:UNP) has “Hold” rating given on Thursday, September 14 by Robert W. Baird. Cowen & Co maintained the shares of UNP in report on Thursday, September 28 with “Hold” rating. BMO Capital Markets maintained the shares of UNP in report on Thursday, November 30 with “Buy” rating. The firm earned “Equal-Weight” rating on Tuesday, October 31 by Morgan Stanley. Stifel Nicolaus maintained Union Pacific Corporation (NYSE:UNP) on Thursday, October 26 with “Hold” rating. The company was maintained on Friday, October 27 by TD Securities.
Investors sentiment increased to 0.94 in Q4 2017. Its up 0.04, from 0.9 in 2017Q3. It is positive, as 49 investors sold UNP shares while 505 reduced holdings. 128 funds opened positions while 391 raised stakes. 598.50 million shares or 0.52% less from 601.66 million shares in 2017Q3 were reported. Highvista Strategies Limited Company holds 0.09% or 2,500 shares in its portfolio. Icon Advisers reported 0.76% stake. Ferguson Wellman Cap Mngmt invested in 0.45% or 96,936 shares. 1.21M are held by Prudential Public Limited Com. Ameriprise Inc accumulated 0.41% or 6.67 million shares. Marathon Asset Ltd Liability Partnership reported 462,779 shares or 0.96% of all its holdings. Voloridge Investment Management Lc has invested 0.04% in Union Pacific Corporation (NYSE:UNP). Broderick Brian C owns 15,234 shares. Integral Derivatives Limited Liability, New York-based fund reported 88,239 shares. Pacad invested 0.38% of its portfolio in Union Pacific Corporation (NYSE:UNP). Curbstone Fincl Mgmt holds 2,610 shares or 0.19% of its portfolio. Boston Mgmt has 0.18% invested in Union Pacific Corporation (NYSE:UNP) for 2,620 shares. Moreover, At National Bank & Trust has 0.06% invested in Union Pacific Corporation (NYSE:UNP) for 4,455 shares. Stearns Financial Services Group Inc Incorporated owns 7,116 shares for 0.23% of their portfolio. Barnett Inc accumulated 26,783 shares.
Analysts await AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) to report earnings on May, 1. They expect $-0.48 EPS, up 54.72% or $0.58 from last year’s $-1.06 per share. After $0.10 actual EPS reported by AMAG Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -580.00% negative EPS growth.
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, makes, develops, and commercializes therapeutics for womenÂ’s health, anemia management, and cancer supportive care in the United States. The company has market cap of $669.00 million. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme , an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. It currently has negative earnings. The firm also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families.
Among 14 analysts covering AMAG Pharmaceuticals (NASDAQ:AMAG), 3 have Buy rating, 1 Sell and 10 Hold. Therefore 21% are positive. AMAG Pharmaceuticals had 46 analyst reports since August 18, 2015 according to SRatingsIntel. As per Wednesday, May 4, the company rating was downgraded by Raymond James. Deutsche Bank reinitiated the shares of AMAG in report on Thursday, September 3 with “Hold” rating. On Thursday, October 27 the stock rating was initiated by Needham with “Buy”. The company was maintained on Thursday, February 15 by Jefferies. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has “Buy” rating given on Tuesday, June 6 by Jefferies. The firm has “Market Perform” rating by Cowen & Co given on Friday, February 3. The firm earned “Strong-Buy” rating on Wednesday, August 19 by Zacks. Leerink Swann maintained the stock with “Outperform” rating in Wednesday, May 4 report. Cantor Fitzgerald maintained AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) on Thursday, February 1 with “Hold” rating. Morgan Stanley maintained the stock with “Overweight” rating in Wednesday, February 28 report.